Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERLOT: Influence of Milk on Erlotinib Pharmacokinetics
2016-001597-15Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Primary endpoint: AUC of erlotinib. Started Oct 2016; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2016-001597-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001597-15.